| P50 | author | Bing Cui | Q55444983 |
| | Samuel H Lai | Q90099407 |
| | Richard Schwab | Q91187033 |
| P2093 | author name string | Christina C N Wu | |
| | Dennis A Carson | |
| | George F Widhopf | |
| | Thomas J Kipps | |
| | Suping Zhang | |
| | Rongrong Wu | |
| | Liguang Chen | |
| | Grace Liu | |
| | Emanuela M Ghia | |
| | Zhuhong Zhang | |
| P2860 | cites work | CD133 antigen expression in ovarian cancer | Q21093306 |
| | Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers | Q21562662 |
| | NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma | Q24308684 |
| | Cancer stem cells: problems for therapy? | Q37815127 |
| | Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer | Q37825148 |
| | Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links | Q38007261 |
| | ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia | Q38270729 |
| | ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome | Q39417011 |
| | Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis | Q39559733 |
| | ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients | Q39779683 |
| | Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells | Q39932297 |
| | The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. | Q39960772 |
| | Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 |
| | CD133 expression defines a tumor initiating cell population in primary human ovarian cancer | Q46789746 |
| | Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders | Q47614258 |
| | A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer | Q81561698 |
| | ROR1 expression is not a unique marker of CLL | Q84513968 |
| | Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a | Q24315721 |
| | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 |
| | Bmi1, stem cells, and senescence regulation | Q24614474 |
| | Identification and characterization of ovarian cancer-initiating cells from primary human tumors | Q24644329 |
| | Cancer stem cells and drug resistance: the potential of nanomedicine | Q26998993 |
| | Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells | Q28264780 |
| | Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance | Q28307294 |
| | Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism | Q28538384 |
| | An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors | Q29615393 |
| | Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides | Q30478184 |
| | Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance | Q30579225 |
| | Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness | Q33250633 |
| | Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome | Q33359495 |
| | Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group | Q33495949 |
| | ROR1 expression correlated with poor clinical outcome in human ovarian cancer | Q33942010 |
| | Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer | Q34137275 |
| | ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth | Q34189274 |
| | Self-renewal as a therapeutic target in human colorectal cancer. | Q34388958 |
| | Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer | Q34420393 |
| | Human aldehyde dehydrogenase gene family. | Q34459055 |
| | Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. | Q34500251 |
| | Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. | Q34569371 |
| | Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis | Q34639023 |
| | Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival | Q35022205 |
| | The onco-embryonic antigen ROR1 is expressed by a variety of human cancers | Q36433018 |
| | Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden | Q36891437 |
| | Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q36912591 |
| | Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin | Q36983929 |
| | New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). | Q37045475 |
| | Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. | Q37320359 |
| | ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice | Q37495234 |
| | Expression of ROR1 in patients with renal cancer--a potential diagnostic marker. | Q37522298 |
| | Epithelial ovarian cancer: Focus on targeted therapy | Q37776846 |
| P433 | issue | 48 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| | neoplastic stem cells | Q1638475 |
| P304 | page(s) | 17266-17271 | |
| P577 | publication date | 2014-11-19 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy | |
| P478 | volume | 111 | |